All posts by imreal

Highly Regarded Cell and Gene Therapy Expert, Dr. Michael Mendicino, Joins NDA Partners as Expert Consultant


News Image

Dr. Mendicino’s extensive experience in CMC regulatory, regulatory strategy, development strategy, and diligence make him a valuable resource to our clients developing cell and gene therapies, gene editing, regenerative medicine, tissue engineering, and xenotransplantation products.

NDA Partners’ General Manager, Eric Fish, announced today that Michael Mendicino, PhD, a highly regarded subject matter expert in cell and gene therapies and related platform technologies, has joined the company as an affiliated Expert Consultant.

Dr. Mendicino serves as a Chief Consultant and advisor for companies on CMC/CMC regulatory, regulatory strategy, development strategy, and diligence in the fields of cell and gene therapies, gene editing, regenerative medicine, tissue engineering, and xenotransplantation.

Dr. Mendicino was formerly an FDA Commissioner’s Fellow and CMC Reviewer in the Office of Cell, Tissue & Gene Therapies (now Office of Tissues and Advanced Therapies) in the Center for Biologics Evaluation and Research (CBER). In this role, he was responsible for reviewing regulatory submissions for biologics and devices, participated in determining product jurisdiction within CBER, and led/co-led special projects assessing INDs across product areas. He also previously worked at four biotech companies in the cell and gene therapies area for companies at different stages of product and clinical development.

According to Dr. Ellen Feigal, Manager of NDA Partners’ biologics practice, “Dr. Mendicino’s extensive experience in CMC regulatory, regulatory strategy, development strategy, and diligence make him a valuable resource to our clients developing cell and gene therapies, gene editing, regenerative medicine, tissue engineering, and xenotransplantation products. We are pleased to welcome him to NDA Partners.”

Dr. Mendicino is an accomplished leader in cell and gene therapies, and supports numerous professional organizations in the cell and gene therapies area. He has served as co-chair of the Alliance for Regenerative Medicine (ARM) Science and Technology Committee and is the current Chair of the CMC Regulatory Task Force, he is a representative on the International Society for Cellular Therapy (ISCT) Legal & Regulatory Affairs Committee, and is a co-founder and Board Member of the Standards Coordinating Body (SCB). He has authored in excess of 22 publications and book chapters including Nature Biotechnology, Cell Stem Cell, Cytotherapy, Circulation, Journal of Clinical Investigation, and Journal of Immunology, in addition to presenting at numerous international conferences.

Dr. Mendicino received his doctorate degree in immunology and bachelor’s degree in medical genetics and molecular biology from the University of Toronto. He operates his own independent consulting firm and his relationship with NDA Partners is non-exclusive.

About NDA Partners

NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email:

SkillGigs, Inc. Announces Hire of Michael Drake as New Controller and Vice President of Finance


News Image

“SkillGigs is doing groundbreaking work that will exponentially improve the hiring process, and I am excited to help them further the mission. I look forward to helping them expand the company by creating operational efficiencies so we can continue to bring the technology to more users.”

SkillGigs, Inc., a leading ecommerce talent marketplace for healthcare and digital professionals, is pleased to announce that Michael (Mike) Drake has joined SkillGigs as the company’s controller and vice president of finance. In this role, Drake is responsible for leading SkillGigs’ financials and reporting, and ensuring the continuous advancement of the company’s operational efficiencies.

As SkillGigs’ controller and vice president of finance, Drake will leverage the deep financial background and strategic business development acumen accumulated over his career. For over three decades, Drake has led various teams in accounting, financial analysis, sales processes and performance measurement. Drake’s most recent role was that of chief financial officer for a private education school. Prior to that role, he was the performance officer for a strategic consulting firm. Drake earned a Bachelor of Arts in Economics from The College of William and Mary, and his MBA from St. Joseph’s University with a concentration in international business administration.

“SkillGigs is doing groundbreaking work that will exponentially improve the hiring process, and I am excited to help them further the mission,” said Drake. “I look forward to helping them expand the company by creating operational efficiencies so we can continue to bring the technology to more users.”

“Mike is a strong addition to help us round out our executive leadership team. Our decision to bring him on board represents the continuation of our leadership investment, and is a clear indication of our extraordinary growth,” said SkillGigs’ Founder and CEO Kashif Aftab.

Founded in 2017, SkillGigs is a marketplace platform that uses AI technology to pair top professionals with employers based on skill matching. Since its start, SkillGigs has grown exponentially and currently has over 125,000 individuals in the marketplace.

“Our ability to attract and obtain top talent in their chosen profession is testament to the evolution of our company,” said SkillGigs’ President Steve Saville. “Earlier this year we announced other key roles across operations, sales, and marketing on our leadership team. The addition of Mike, along with other recent hires in strategic sales and marketing, have us primed for great success.”

About SkillGigs

SkillGigs, Inc. is an ecommerce talent marketplace that pairs skilled healthcare and technology job seekers with AI-matched work opportunities. Founded in 2017 on the belief that companies and talent should be able to interact seamlessly, SkillGigs is dedicated to empowering the users. SkillGigs elevates and maximizes the hiring process by removing traditional barriers. The company’s patented AI software matches talent with jobs tailored to their skills, while giving companies with open positions strong candidates who are ready to work—all without a single recruiter. Learn more at skillgigs.com.

Share article on social media or email:

Andgo Systems Closes $5.6 M Series A Funding Round, Co-Led by First Ascent Ventures and Waterline Ventures


Andgo Logo

Andgo is positioned as the category leader in driving intelligent shift fill automation in complex industries with unique staffing challenges, such as healthcare & manufacturing. We focus significant effort on providing flexible tools to make the lives of nurses and other frontline employees easier.

Andgo Systems (“Andgo”), a leading provider of intelligent workflow automation solutions for dynamic absence onboarding, shift filling, and vacation mapping, announced today it has raised $5.6 Million CAD in Series A funding. The round was co-led by First Ascent Ventures and Waterline Ventures, based out of Toronto and Boston, respectively.

Andgo drives transformational intelligent automation for organizations in industries (such as healthcare) that have complex requirements around onboarding employee absences, filling vacant shifts, and annual vacation selection & awarding. Andgo’s suite delivers end-to-end automation throughout what are traditionally highly manual, tedious processes. Andgo’s customers gain actionable insights, accurately filling more shifts faster.

“This funding will help Andgo address the far-reaching shift filling challenges that organizations are facing,” said Tom Ross, Co-Founder, and CEO, Andgo Systems. “Andgo is positioned as the category leader in driving intelligent shift fill automation in complex industries with unique staffing challenges, such as healthcare and manufacturing. We focus significant effort on providing flexible tools to make the lives of nurses and other frontline employees easier.”

The company has seen strong momentum, adding new customers across North America in major healthcare organizations. A growing Andgo team will allow the company to meet demand, as organizations race to modernize their approach to deal with scheduling challenges such as shrinking budgets, staffing shortages, and employee satisfaction/retention.

“Andgo is changing the game for how large organizations can tackle very complex workforce scheduling challenges,” said Tony van Marken, Managing Partner at First Ascent Ventures. “Our investment in Andgo reflects our belief in the tremendous market potential for their technology and management’s ability to execute on their vision. Andgo has demonstrated an ability to deliver value to the most demanding companies on a consistent basis, which is exemplified by their 100% customer retention rate. We are very excited to partner with Andgo and welcome them to the First Ascent portfolio.”

“We are excited to support Andgo as they continue to scale their disruptive solutions, particularly in healthcare,” said Robbie Greenglass, Managing Partner at Waterline Ventures. “With workforce trends affecting employee availability and satisfaction, healthcare organizations need to innovate in order to thrive. Andgo is well positioned to deliver on helping organizations with this transformation.”

About Andgo:

Our mission at Andgo is to improve the lives of both our customers and employees. We do this by enabling meaningful and thoughtful work that simplifies complex interactions related to dynamic shift filling and vacation mapping. Andgo’s intelligent workflow automation suite fills more shifts faster, with the right people. Our holistic, end-to-end approach drives significant ROI to our customers, particularly in high-volume scheduling environments. For more information, visit our website: http://www.andgosystems.com

About First Ascent Ventures:

First Ascent Ventures invests in emerging technology companies that are building the next generation of disruptive, enterprise B2B software that leverages the cloud, artificial intelligence (AI), machine learning, big data, 5G, mobility, and IOT with a focus on companies that are solving the challenges related to data privacy and security in the enterprise. First Ascent Ventures is looking for outstanding, committed entrepreneurs and management teams who seek not just financial backing, but the experience and expertise of successful financial and operating executives who can create a catalyst for growth and ultimately a successful exit for all stakeholders.

For more information, please visit http://www.firstascent.vc

About Waterline Ventures:

Waterline Ventures invests in the early stage healthcare technology and services companies that are improving the way care is delivered. Increasing costs, inconsistent quality, and inadequate access to healthcare create the need for innovation. There is a massive and growing opportunity for technological transformation in healthcare. Their entrepreneurs are leading the change within healthcare.

For more information, please visit http://www.waterlineventures.com

# # #

Share article on social media or email:

Ohio Recovery Center Now Open Helping Those on the Road to Recovery


News Image

We are thrilled to bring the same exceptional level of care we offer at our five Massachusetts facilities to those in need throughout the state of Ohio and surrounding areas.

Ark Behavioral Health, a renowned behavioral healthcare provider headquartered in Massachusetts, has opened its first out-of-state addiction treatment center in Van Wert, Ohio. The Ohio Recovery Center is a 50-acre campus offering medical detox and residential treatment for drug and alcohol abuse and addiction.

“We are thrilled to bring the same exceptional level of care we offer at our five Massachusetts facilities to those in need throughout the state of Ohio and surrounding areas,” says Richard McDonald, CEO of Ark Behavioral Health.

Creating and filling over 70 full-time positions, the multidisciplinary staff boasts a variety of treatment professionals with varying degrees of education, independent licensure, and specialized training. The Ohio Recovery Center has received licensure and accreditation from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and The Substance Abuse and Mental Health Services Administration (SAMHSA) in addition to the Ohio Department of Mental Health and Addiction Services (Ohio MHAS).

“We have the best of the best on board. We selected the state of Ohio to open our new treatment facility due to the fact it has been at the epicenter of the opioid epidemic.”

This comes at a time when Ohio is facing an influx in drug use; according to the Ohio Department of Health, over 5,000 Ohioans died of drug overdoses in 2021—the highest number ever recorded in the state. Some of the most dangerous drugs in the state include cocaine, alcohol, methamphetamine, heroin, and fentanyl.

“While the opioid epidemic tends to generate significant attention from the media, it is important to point out that the most abused substance in the country is alcohol. A report from America’s Health Rankings stated that 17.7% of Ohio residents participated in excessive drinking over the past year.”

The impressive facility includes an array of amenities, such as a basketball gymnasium, fitness center, multiple walking paths, volleyball court and baseball field. The Ohio Recovery Center takes pride in performing individualized treatment planning using evidence-based treatment modalities as well as 12-step immersion and peer support.

“The facility is immaculate, and we have created a safe space for individuals to launch their journey in recovery.”

Addiction and recovery experts are available for interviews.

For more information, visit: http://www.recoveryohio.org

About Ark Behavioral Health

Ark Behavioral Health provides all levels of evidence-based care to help people begin their personal journey toward recovery. Their commitment to patients is unmatched and proven by their six diverse treatment locations. Ark Behavioral Health specialists put the client’s needs first throughout the treatment process, which is supported by caring and professional staff.

Share article on social media or email:

Zea Biosciences Launches Master Research Collaboration Agreement with Loma Linda University Health


News Image

“The results from this could allow us to fundamentally change manufacturing and the way a product is managed; the hope is we can make a cheaper drug and offer that benefit for everyone, providing wellness across the world.”

Zea Biosciences, a Boston-based biopharmaceutical company with a new platform for biologics and vaccine development, has signed a master research collaboration agreement (MRCA) with Loma Linda University Health (LLUH). The strategic partnership will rapidly scale and develop new therapies and vaccines for a variety of important health issues here and around the world. Zea recently gifted some equipment to LLUH to help their research and to share process development data.

“We are very excited about this collaboration with Loma Linda University Health, as it is a beneficial relationship for both of our organizations,” said Jim Wilson, founder of Zea Biosciences. “The results from this could allow us to fundamentally change manufacturing and the way a product is managed; the hope is we can make a cheaper drug and offer that benefit for everyone, providing wellness across the world.”

Dr. William Langridge, principal researcher for plant molecular genetics at Loma Linda University Health, has been developing vaccines for years without the ability to rapidly scale the products. Zea’s Lighthouse platform provides the opportunity to scale-up and develop the necessary quantities for clinical trials and eventually commercialization.

Charles Legg, CEO of Zea Biosciences, stated, “This is a great opportunity to truly collaborate and share important data as Dr. Langridge and his team continue to do their great research and we look to help enable that work to get to the next stage and into clinical trials. We hope this is a model that will show the way to many other significant collaborations for Zea and a community dedicated to developing therapies that can be shared with the world.”

“Working in conjunction with the researchers at Loma Linda University Health, we have an opportunity to make a real impact,” said Wilson.

# # #

About Zea Biosciences: Boston-based Zea exists to grow access to reliable medicines to inspire healthier communities. As a plant biotechnology platform focused on identifying, producing, and growing high-potency drugs, we are on a mission to unlock as many therapies for as many people as possible. Zea’s motto: Unlock the possible. The Zea Lighthouse earned top honors as a finalist in Fast Company’s 2022 World Changing Ideas. Zea is part of an influential short list of US companies that are working to make the world a better place. Learn more at http://www.zeabio.com.

About Loma Linda University Health (LLUH): Loma Linda University Health includes Loma Linda University’s eight professional schools, Loma Linda University Medical Center’s six hospitals — including The Dennis and Carol Troesh Medical Campus, which opened in August 2021, housing the new adult hospital and Children’s Hospital expansion — and more than 1,000 faculty physicians located in the Inland Empire of Southern California. Established in 1905, Loma Linda University Health is a global leader in education, research and clinical care. It offers over 100 academic programs and provides quality health care to over 40,000 inpatients and 1.5 million outpatients each year. A Seventh-day Adventist organization, Loma Linda University Health is a faith-based health system with a mission “to continue the teaching and healing ministry of Jesus Christ.”

Share article on social media or email:

Cutting-Edge Manufacturing for Cell and Gene Therapies Just Got the Boost it Needs


Virtuosi® powered by QxP, the world’s first virtual reality education platform for pharmaceutical manufacturing

Cell and gene therapies can save lives right now, but the challenges around manufacturing are often the rate-limiting step…

Virtuosi® powered by QxP, the world’s first virtual reality (VR) education platform for pharmaceutical manufacturing, has expanded its offering, announcing a suite of state-of-the art video content and highly immersive VR training experiences for cell and gene therapies production.

Advanced Therapy Medicinal Products (ATMP’s), comprising cell, gene, and tissue-engineered therapies, are delivering breakthroughs in the treatment of diseases, and are widely acknowledged to be the future of medicine. Yet the sophisticated manufacturing facilities, exacting training requirements, and complex bioprocessing procedures make these advanced therapies much more costly and demanding to produce.

“Traditional methods are not working to effectively and quickly train the thousands of new operators being hired for the intricate processes required to produce advanced therapies,” explained Brian Duncan, COO of Quality Executive Partners, Inc. (QxP), the inventor of Virtuosi. “Cell and gene therapies can save lives right now, but the challenges around manufacturing are often the rate-limiting step in getting these drugs to the patients whose lives depend on them. We understand that time is of the essence, and our Virtuosi development team had to move fast.”

“There are big challenges that we need to work on together right now to secure the future and potential of ATMPs for patients,” said Dr. Heather Main of ATMP Sweden. “I have found Good Manufacturing Practices (‘GMP’) for the ATMP field to be an extremely exciting space with currently limitless opportunity for learning and exponential growth with currently few ‘experts’ in the diversity of critical areas.”

Advanced therapies, often custom-produced for each individual patient, are expensive, sometimes costing more than a million dollars per treatment. “Making mistakes is not an option: there are patients waiting for potentially life-saving treatments, and it is not an option for the companies that need to be efficient and cost-effective to keep producing more treatments,” noted Duncan.

Sterile manufacturing in pharma has seen strong benefits in using VR, as Virtuosi is already widely deployed in large and smaller enterprises, significantly reducing error rates and greatly speeding up training programs, improving training effectiveness and delivery of product.

About Virtuosi

Virtuosi powered by QxP is the world’s first and only comprehensive multi-language immersive training platform for pharmaceutical manufacturing operators in aseptic processing, microbiology, and cell and gene therapy processing. The immersive platform combines in-depth, precision-focused teaching videos with highly immersive virtual reality experiences through which employees apply and practice the techniques they learn. Practice makes perfect. Virtuosi is available in English, French, German, Spanish, and Swedish. https://www.virtuosivr.com/

About Quality Executive Partners, Inc.

Quality Executive Partners, Inc. (QxP) is a global management consulting and educational technology firm providing the pharmaceutical industry with innovative solutions and revolutionary technical education programs, including Virtuosi®. QxP’s experienced team of experts advises pharmaceutical and life sciences companies around the globe. It is in our experience resolving operational and technical manufacturing and quality issues that affords a pragmatic and strategic risk-prioritized approach, achieving your business objectives for submissions, product and site approvals, commercial manufacturing, and workforce readiness . 

https://www.qualityexecutivepartners.com/

Share article on social media or email:

Fenway Health Provides Blueprint for More Effective Federal Response to Monkeypox


Square Blue Fenway Health Logo with White Text

Right now, in the United States, we have the tools stop the spread of monkeypox, which is disproportionately affecting gay and bisexual men—particularly those who are Black and Hispanic.

As U.S. monkeypox diagnoses top 21,000 amid the federal government’s failure to contain the initial outbreak of the virus in May, Fenway Health has released a policy brief that offers solutions to a range of problems that have exacerbated the spread of the virus.

Among Fenway Health’s policy recommendations are invoking the Defense Production Act to scale up monkeypox vaccine production, monitoring the efficacy of the new intradermal vaccination strategy, making free testing widely available, educating patients and providers about available treatments, and FDA authorization to use TPOXX—a treatment approved for smallpox—to treat monkeypox.

“Right now, in the United States, we have the tools stop the spread of monkeypox, which is disproportionately affecting gay and bisexual men—particularly those who are Black and Hispanic,” said Sean Cahill, PhD, Director of Health Policy Research at the Fenway Institute, who co-authored the policy brief. “We have stockpiles of medications to treat monkeypox, effective vaccines to protect us from the virus, and effective testing. We have the infrastructure and know-how from managing the COVID-19 and HIV epidemics to craft a robust national response and immediately stop the needless suffering of thousands of Americans.”

As of September 9, more than 21,000 U.S. residents have been diagnosed with monkeypox, although most U.S. experts believe cases are undercounted due to limited access to testing and a reluctance by many people to seek care because of social stigma about the disease. Stigma has been exacerbated by the presence of sores on the face and trunk, anal sores, and the virus’ association with same-sex sexual activity, as 98 percent of diagnosed cases in the U.S. and other parts of the world in 2022 are among gay and bisexual men and other men who have sex with men.

The U.S. has failed to contain monkeypox by failing to effectively mobilize existing public health infrastructure to aid communities affected by the virus. Stockpiles of vaccines which can be used to protect against monkeypox have been rendered inaccessible due to bureaucratic delays coupled with miscalculations about how quickly the virus would spread and how great vaccine demand would be. Monkeypox testing was initially hobbled by complex protocols which effectively rationed testing, delayed the identification of cases, and hampered efforts to track the spread of the virus.

Due to poor health communication, many providers and patients are unaware that treatment for monkeypox is available. And because existing antiviral treatments for monkeypox are currently authorized for treating smallpox and not monkeypox, providers who are aware of this treatment must complete complex paperwork that can take several hours per patient to complete. Many patients have been consequently forced to endure the painful lesions caused by the virus with no relief. Finally, these issues have occurred within the context of racial/ethnic, class, and geographic inequities in health care access which have been exacerbated during the monkeypox outbreak, as marginalized communities have difficulty accessing vaccines and treatments concentrated in the hands of a few well-resourced institutions, some of which are located in areas that are less accessible to communities of color.

“It’s not too late to make a course correction. Policy makers and public health officials must adopt an aggressive strategy of testing, treatment, vaccination, and public education if we are to eradicate monkeypox,” said Thomas Freitag, MPP, a Fenway Institute Research Fellow and co-author of the policy brief. “We have a rare opportunity to stop a major outbreak in its tracks but we must take full advantage of the resources and expertise at our disposal.”

Among the policy recommendations, invoking the Defense Production Act represents a valuable legislative tool for facilitating the rapid manufacture and allocation of critical national supplies and could address a current shortage of JYNNEOS vaccines, a two-dose vaccine that helps protect against monkeypox and smallpox. This act gives the president the power to expand the production of materials important for national defense, by requiring businesses to accept production contracts and to utilize financial incentives to convince industries to expand their production capacity.

At the same time, public health researchers must be diligent in studying the intradermal vaccination strategy authorized by the Food and Drug Administration (FDA) in August 2022 and monitoring the efficacy of this approach. With this approach, the vaccine is administered between layers of skin rather than subdermally, or below the skin, and up to five doses of the vaccine can be administered from one vial of the JYNNEOS vaccine. Close monitoring of the intradermal vaccination strategy is especially important as experts have raised concerns that it does not provide sufficient protection for those with compromised immune systems, such as people living with HIV.

Testing should replicate the government’s successes during the COVID-19 pandemic—making monkeypox tests free regardless of insurance status to minimize the impact of financial barriers and utilizing the NIH’s RADx initiative—which provided funding for new technology and projects focused on increasing COVID testing access and equity—to develop new monkeypox testing methods and foster equitable access.

Provider and patient education is also critically needed to ensure that individuals can access treatment, as many of them are unaware that antiviral therapeutics are available for painful lesions and those that encroach on sensitive areas such as the eyes.

The FDA should authorize the use of TPOXX for monkeypox, as European public health authorities have already done, to facilitate access to an important therapeutic tool and minimize the suffering of monkeypox patients.

Finally, Congress must appropriate funding for the monkeypox response and for research to better contain and eliminate the virus. Republicans in the Senate are opposing President Biden’s request for funding, claiming that it will exacerbate inflation. “Congress has failed to fund the public health response to monkeypox,” said Cahill. “They need to act now to support critically needed prevention, care and research.”

The Fenway Health policy brief also calls on President Biden to work with the World Health Organization and allies to organize a global relief effort to eliminate monkeypox from central and western Africa, where it has been causing suffering and death for more than half a century.

Download “How The Federal Government Can Better Respond To The Monkeypox Outbreak” here.

Share article on social media or email:

Asymmetrex’s Introduction of Online Calculators for Determination of the Dosage of Therapeutic Stem Cells Announced as a Reformation in Stem Cell Science and Medicine


News Image

Console page from Asymmetrex® online calculator portal for determining the dosage of umbilical cord blood stem cells

…introduction of online rapid stem cell-counting calculators is the start of a reformation in stem cell science and medicine.

In 2020, when Asymmetrex® published the seminal report of its innovation for counting therapeutic tissue stem cells for the first time, the company’s President & CEO, James L. Sherley, M.D., Ph.D., says, “the method was already very good, but anything but routine.”

Before Asymmetrex® developed the rapid stem cell-counting calculators formally introduced today, executing its stem cell-counting technology required 3 to 4 weeks of intensive, expensive cell culture procedures. However, the company used its earlier advance to define proprietary mathematical equations, which now power the company’s online rapid-counting calculators. With an online calculator, a user can routinely get the stem cell dosage of cell preparations from any human tissue after culturing a small sample of the cells for only 72 hours.

Asymmetrex® recently completed the validation of its technology head-to-head with the gold standard SCID mouse assay for estimating the dosage of human blood stem cells, which are widely used for approved stem cell transplantation therapies. The SCID mouse assay was never adopted for routine use because it is expensive, requires 30-40 mice for a single count, takes more than 16 weeks to complete, and is unreliable. It also only works for blood stem cells. In contrast, Asymmetrex’s online rapid-counting calculators give an instant stem cell count from a user’s input of conventional cell data from only 72 hours of inexpensive cell culture. And calculators are available for stem cells from all types of human tissues, not just blood stem cells.

There are custom calculators for different stem cell tissue sources and culture conditions. CEO Sherley relates that, “There are hundreds, if not thousands, of rapid stem cell-counting equations waiting to be mined by our software.” The company is already offering generic calculators for five different types of stem cells commonly used in research, approved therapies, and many ongoing stem cell clinical trials. Asymmetrex® can also develop proprietary counting equations for proprietary stem cell sources and production conditions.

Previously, many companies who produced and used tissue stem cell products and treatments were resigned to not knowing their stem cell dosage, because no convenient method was available to determine it. But dosage information was always needed to better ensure sufficient stem cells for effective treatment and to prevent the waste of scarce stem cells due to unaware excessive dosing.

Asymmetrex® has produced educational online forums and podcasts to reform ideas in stem cell science and stem cell medicine on the importance of attention to stem cell dosage for accelerating progress in stem cell research and therapy. Says Sherley, “Our company’s introduction of online rapid stem cell-counting calculators is the start of a reformation in stem cell science and medicine.”

About Asymmetrex®

Asymmetrex®, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – stem cell-specific quantification and stem cell expansion – that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex® is a member company of the Advanced Regenerative Manufacturing Institute|BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio). The company’s development of online calculators for rapid stem cell counting has been funded by R&D grants from ARMI|BioFabUSA and the National Heart, Lung, and Blood Institute.

Share article on social media or email:

CS Analytical Granted Controlled Dangerous Substance License


News Image

The CDS License will allow us to better serve the container testing needs for those manufacturers of controlled drugs.

CS Analytical Laboratory, the world’s only FDA regulated contract laboratory exclusively dedicated to providing regulatory solutions and qualification testing services specifically for drug product and medical device container systems, is pleased to announce that it has been granted a Controlled Dangerous Substance license for scheduled drugs under section II through V. The license, granted by the New Jersey Department of Consumer Affairs, in conjunction with the Federal Drug Enforcement Agency, enables CS Analytical to perform testing on controlled and classified drug substances.

“Achievement of a CDS License requires a lengthy and strict adherence to a large number of special requirements and I want to thank the CS Analytical team for their diligence in helping put this program together. The CDS License will allow us to better serve the container testing needs for those manufacturers of controlled drugs,” commented Sandra Cincotta, Director of Quality for CS Analytical.

Controlled drugs utilize a wide variety of container and package configurations that require testing. A number of test protocols require the use of the drug product as part of the test process. For example, dose volume measurements are best performed with actual drug product. The ability to be able to receive, store and perform testing using a controlled drug product allows the CS Analytical Team to meet client and regulatory test requirements in a real-life scenario. CS Analytical has implemented a number of required controls that include the installation of a DEA approved safe, a central station monitored security system and specific and detailed operating procedures around all aspects of handling and using CDS drugs in the testing process.

About CS Analytical Laboratory

The only FDA regulated, cGMP laboratory dedicated exclusively to the complex world of drug and medical device container and package qualification testing, the CS Analytical Team includes the world’s leading experts on all relevant USP and EP requirements and the thought leaders and pioneers on CCI (container closure integrity – CCI) testing. Offering a full suite of laboratory services to include all USP, EP and JP procedures specific to glass, plastic and elastomers as well as complete USP 1207 services that span basic feasibility studies, component qualification programs and advanced method development and validation for helium leak testing, vacuum decay, high voltage and headspace analysis leak testing. CS Analytical is the one source that can ensure your medical product container and package system meets the strict and complex regulatory requirements.

Share article on social media or email:

Lightning strikes twice at the same time, 137 miles apart


We’re grateful to our collaborators for all they are doing to advance pharmaceutical development in space and are thrilled to be a part of these studies that may alter the future development of pharmaceutical products as we know it

Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma’s mission. In 2021, Improved Pharma had the unique opportunity to start polymorph screening research projects in close collaboration with Varda Space Industries with the intent of advancing pharmaceutical product manufacturing. As a result, the Improved Pharma/Varda team has developed a process to prepare Form III of Ritonavir using a faster nucleation method.

In 1998, the recall of ritonavir upon the unexpected appearance of the more stable Form II polymorph, still remains a notorious case of disappearing polymorphs as the presence of Form II inhibited the ability to grow the original Form I. The current research presents the characterization of Form III of ritonavir grown from melt/cool crystallization. While Form III has been observed by researchers in 2014 and 2022, this study presents a thorough characterization and novel thermal profile for quicker nucleation and crystallization of the new form. In this current study, past thermal methods are expanded upon by examining the polymorphic landscape of ritonavir to shed light on the crystallization of Form III from the melt.

“This ongoing research effort in collaboration with Varda Space Industries has been very exciting for the entire Improved Pharma team,” exclaims Dr. Stephen Byrn, CSO of Improved Pharma. “We’re grateful to our collaborators for all they are doing to advance pharmaceutical development in space and are thrilled to be a part of these studies that may alter the future development of pharmaceutical products as we know it.”

Ritonavir Form III: Lightning strikes twice at the same time, 137 miles apart

Stephan D. Parent1, Pamela A. Smith1, Dale K. Purcell1, Daniel T. Smith1, Susan J. Bogdanowich-

Knipp1, Ami S. Bhavsar2, Larry R. Chan2, Jordan M. Croom2, Haley C. Bauser2, Andrew McCalip2,

Stephen R. Byrn1, Adrian Radocea2*

1. Improved Pharma LLC, West Lafayette, IN 47906

2. Varda Space Industries, El Segundo, CA 90245

*Corresponding Author: adrian@varda.com

https://doi.org/10.26434/chemrxiv-2022-49tzw

About Improved Pharma

Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes. Services include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting for the development and defense of intellectual property matters. The company was founded in 2006 by Stephen and Sarah Byrn, who also founded SSCI.

For more information about Improved Pharma’s services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

About Varda Space Industries

Varda is a venture capital-backed company creating the first free-flying space stations and reentry vehicles ready-built for materials processing. Microgravity found in low Earth Orbit (LEO) makes it possible to precisely control the crystallization process during development and manufacturing to create valuable pharmaceutical products that cannot be created on Earth’s surface. Varda has raised $53m+ from a cadre of world-class venture capital firms including, but not limited to: Founders Fund, Lux Capital, Caffeinated Capital, Khosla Ventures, and General Catalyst.

For more information about Varda please contact press@varda.com

Share article on social media or email: